Rethinking mental health research through AI-driven simulations

Recent research highlights generative agents’ potential to model complex socio-environmental interactions, transforming mental health studies and interventions.

Cybin Reports Fiscal Year 2024 Financial Results and Recent Business Highlights | Psychedelic Invest

Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment

June 26, 2024

BIOSECURE Act could impact US biopharma drugs with half in clinical-stage development

The BIOSECURE Act could impact more than 120 US biopharmaceutical drugs in development by companies partnered with Chinese contract development and manufacturing organisations (CDMOs) and

June 4, 2024

The Biggest Psychedelic News This Week – October 16th | Psychedelic Spotlight

Over his fifty-year tenure at the Johns Hopkins School of Medicine, Dr. Griffiths dedicated years to investigating the effects of mood-altering substances, including opiates, cocaine,

October 21, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.